Prostate cancer: to screen or not to screen?
The debate about the usefulness of population-based prostate cancer screening has been ongoing for decades. The most current evidence shows limited benefit of population screening, and significant psychological, physical and financial costs. Efforts to improve screening with better markers and more selective treatment may make population-based screening more effective.
Division of Urologic Surgery, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center, 4960 Children's Place, Campus Box 8242, St Louis, MO 63110, USA.
Alex
A
Shteynshlyuger
Gerald L
GL
Andriole
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D017281:Cost of Illness; D051517:Digital Rectal Examination; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011788:Quality of Life; D012307:Risk Factors
D015415:Biomarkers; D017430:Prostate-Specific Antigen